CNS MALIGNANCIES

Educational session FPON Muhammad Zulfiqar, MD January 2021

Conflict of Interest

Nothing to declare





Objectives

- Recognize early signs and symptoms
- Describe current management
- Discuss supportive care and the role of the family physician.
- Discussion of questions and comments


What is estimated in Canada

- In 2020, an estimated:
- 3,000 Canadians will be diagnosed with brain and spinal cord cancer.
- 2,500 Canadians will die from brain and spinal cord cancer.
- 1,700 men will be diagnosed with brain and spinal cord cancer and 1,400 will die from it.
- 1,350 women will be diagnosed with brain and spinal cord cancer and 1,050 will die from it.

Incidence

RELATIVE FREQUENCIES OF GLIOMAS





Roman numerals denote World Health Organisation (WHO) tumour grades. Redrawn from: Preusser M, et al. Ann Neurol 2011;70(1):9-21.




Looks can be deceiving

How does it look? Vs How it behaves?

How it looks?

 Prominent anaplasia, vascular proliferation and palisading of tumor cells around necrosis



How it Behaves?

- IDH wild-type
- glioma with TERT mutations and polysomy of chromosome 7
- plus loss of heterozygosity of chromosome 10q have similar
- outcomes compared with those with GBM


 Aibaidula A, Chan AK, Shi Z, et al. Adult IDH wild-type lower-grade gliomas should be further stra if ed. Neuro Oncol. 2017;19:1327-1337.
Wijnenga MMJ, Dubbink HJ, French PJ, et al. Molecular and clinical heterogeneity of adult diff use low-grade IDH wild-type gliomas:

assessment of TERT promoter muta on and chromosome 7 and 10 copy number status allows superior prognos c stra fi ca on. Acta Neuropathol. 2017;134:957-959.

Current WHO Classification

WHO CLASSIFICATION





*Characteristic but not required for diagnosis.



- Headache
- Seizure
- Focal neurological symptoms
- Cognitive issues

- Headache
- Seizure
- Focal neurological symptoms
- Cognitive issues


- Headache
- Seizure
- Focal neurological symptoms
- Cognitive issues

- Headache
- Seizure
- Focal neurological symptoms
- Cognitive issues

- Headache
- Seizure
- Focal neurological symptoms
- Cognitive issues

Objectives

- Recognize early signs and symptoms
- Describe current management
- Discuss supportive care and the role of the family physician.
- Discussion of questions and comments



PHASE III TRIAL OF CONCOMITANT AND ADJUVANT TEMOZOLOMIDE AND RADIOTHERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME

Roger Stupp, WP Mason, MJ Van Den Bent, M Weller,

B Fisher, M Taphoorn, AA Brandes, G Cairncross,


D Lacombe, RO Mirimanoff

On behalf of the European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group

ASCO Plenary Session / June 7, 2004

EORTC 26981-22981 and NCIC CE.3


Treatment Schema




 Temozolomide 75 mg/m² po qd for 6 weeks, then 150–200 mg/m² po qd d1–5 every 28 days for 6 cycles
Focal RT daily — 30 x 200 cGy Total dose 60 Gy

*PCP prophylaxis was required for patients receiving TMZ during the concomitant phase.


85 institutions, 14 countries, 573 patients Patient Accrual



Progression Free Survival



Overall Survival




%

45 years old gentleman

- Glioblastoma
- Treated with STUPP protocol.

Images



Appropriate next step:


- 1. Disease progression. Move to second line treatment
- 2. Options are limited. Continue same treatment.
- 3. Re-image in 8 weeks
- 4. Continue same treatment as it falls into the right timeframe of pseudo progression

Bavacizumab at Progression


- Phase 2
- 6 month PFS of 40% to 50%
- Median OS of 8 to 9 months.

J Clin Oncol. 2009;27(28):4733. Epub 2009 Aug 31

Pseudo improvement



Course of Events



Checkpoint Inhibitors

Checkpoint inhibitors gliomas

- 1. Have game changing effect
- 2. Are under investigation
- 3. Not as promising as they are in other solid tumors

FDA Approval of Checkpoint Agents

Drug Name	Company	Mode of Action	Cancers Treated	Year approved
Opdivo/Nivolumab	Bristol-Myers Squibb	Anti-PD-1	Bladder Colorectal Liver	2017
			Head and Neck Hodgkin's Lymphoma Renal Cell CA	2016
			NSCLC Melanoma	2015 2015
			Melanoma	2013
Atezolizumab	Genentech	Anti-PD-L1	Lung Bladder	2016
Durvalumab	Medimmune/A straZeneca	Anti-PD-L1	Bladder Lung	2017
Avelumab	Pfizer	Anti-PD-L1	Merkel Cell Bladder	2017

PRESENTED AT: 2018 ASCO ANNUAL MEETING #ASCO18 Slides are the property of the author, permission required for reuse.

Presented By Gavin Dunn at 2018 ASCO Annual Meeting

FDA Approval of Checkpoint Agents

Drug Name	Company	Mode of Action	Cancers Treated	Year approved
Keytruda/ Pembrolizumab	Merck	Anti-PD-1	MSI High Bladder Stomach/GE Lung (first line) Lymphoma	2017
			Lung Head and Neck	2016
			NSCLC Melanoma	2015 2014
Nivolumab + Ipilimumab	Bristol- Myers Squibb	Anti-PD-1 + Anti-CTLA-4	Metastatic Melanoma	2015
Yervoy/Ipilimumab	Bristol- Myers Squibb	Anti-CTLA-4	Metastatic Melanoma	2011

PRESENTED AT: 2018 ASCO ANNUAL MEETING #ASCO18 Sildes are the property of the author, permission required for reuse.

Presented By Gavin Dunn at 2018 ASCO Annual Meeting


Ongoing Experience with Checkpoint Blockade in Glioblastoma

- CheckMate-143: randomized trial of Nivolumab (anti-PD-1) compared to Bevacizumab in recurrent GBM (N = 369 patients)
 - No difference in OS-12 (42%) or median OS (9.8 vs 10 months)
- CheckMate-498 (Methylated): An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma
- CheckMate-548 (Unmethylated): An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma




Presented By Gavin Dunn at 2018 ASCO Annual Meeting

Window of Opportunity Clinical Trials to Monitor Immune Responses in GBM patients



Presented By John De Groot at 2018 ASCO Annual Meeting

Data in Context of Biomarker Predictors for Response to Immune Checkpoint Inhibitors



Hodges, Neuro-Oncology, 2017; Garber, Neuro-Oncology, 2016; Nduom, Neuro-Oncology, 2015

Presented By John De Groot at 2018 ASCO Annual Meeting

Objectives

- Recognize early signs and symptoms
- Describe current management
- Discuss supportive care and the role of the family physician.
- Discussion of questions and comments

DR. EVANGELOS MICHELAKIS University of Alberta






IAY CONVICTED SEX OFFENDER ALFONSO RODRIGUEZ WAS SE

DCA's Promise at two levels

- Electrical
 - High mitochondrial memberane potential
 - Low expression of K+ channels
- Metabolic
 - Aerobic glycolysis


DCA




DCA LACK OF CLINICAL STUDIES

Tumor Treating Fields

- Mitotic arrest and apoptosis
- Increased sensitivity to chemotherapy in the presence of TTF




Tumor Treating Fields



Findings

- 210 patients randomized to TTFields plus temozolomide
- 105 randomized to temozolomide alone
- Stopped early due to ongoing benefit.
- median follow-up of 38 months (range, 18-60 months)
- PFS 7.1 months vs 4.0 months.
- OS 20.5 months vs 15.6 months.
- No increase in toxicity
- Main side effects from TTF was skin irritation, rash, ulceration and infection.



Mind body medicine


- 1. Is a new age popular term with no scientific merits
- 2. Field of neuro-immunology supports evidence that mind plays pivotal role in healing
- 3. If there is any role, it is very limited at its best.



Mind Body Medicine: Guiding Patients to Health & Happiness

Oct 19-21, 2017 Boston, MA

Featuring Mind Body Medicine Pioneers Herbert Benson, MD and Jon Kabat-Zinn, PhD








MBSR (Mindfulness based stress reduction)

Does increased stress promote cancer growth?

- Thaker et al (MD Anderson)
- Nude mice model (inoculation with ovarian cancer cells)
- Stressed out mice (growth rate 275% more than non stressed)
- Beta adrenergic receptor expression on tumor cells.
- Transcriptional upregulation of VEGF

Can decreasing stress have improvement in cancer outcome?

- Cancer. 2008;113:3450– 3458. OSU and Walther Cancer Insitute and NCI.
- Adjuvant Breast cancer (N=212)
 - Randomization between intervention (26 sessions teaching strategeis to reduce stress, improve mood and alter heatlh behaviors vs assessment only)
- 11 yrs of follow up
- Median survival 6.1 vs 4.8 yrs.
- Multivariate analysis HR 0.44; p=0.016)




In 4 weeks Increase NK cells 61% ;p=<0.01 reduction of cancer cells in exercising mice

Pedersen L, Idorn M, Olofsson GH, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab. 2016;23:554–562.

Exercise in high grade Glioma

- 243 patients with high grade glioma
- KPS 70 or higher
- Self administered questionnaire on exercise behavior
- 6 minute walk to assess functional cpacity.
- Exersice was better preditor of survial than KPS, age, sex, grade and number of prior progressin
- Adjusted HR 0.64 (95% CI 0.46-0.91)
- Strenous exercise was independent predictor of survival.



Ruden E, Reardon DA, Coan AD, et al. Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. J Clin Oncol. 2011;29:2918–2923

Nutrition

- Joint Study at PMH and Harvard Medical School.
- Thompson LU, Chen JM, Li T, et al. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res. 2005;11:3828–3835.

Breast cancer patietns

- randomized to daily intake of either a 25 g flaxseed containing muffin (n = 19) or a control (placebo, n=13) muffin
- Reductions in Ki-67 labeling index (34.2%; P = 0.001) and in c-erbB2 expression (71.0%; P = 0.003) and an increase in apoptosis (30.7%; P = 0.007) were observed in the flaxseed, but not in the placebo group.
- Potential to reduce tumor growth.

Summary

- STUPP protocol remains standard of care
- Unique microenvironment of GBM does not allow immune check point inhibitors to work most effectively.
- There are no available clinical trial evidence for DCA
- In right situation, TTF is reasonable option to try as first line treatment.
- Several innovative combination immunomodulatory treatments are under active investigation
- Think about open clinical trial.
- Mind body medicine needs more attention going forward in an ever increasing field of expensive targeted interventions.

Objectives

- Recognize early signs and symptoms
- Describe current management
- Discuss supportive care and the role of the family physician.
- Discussion of questions and comments

Questions and Comments

